Treatment With Liraglutide as add-on to Insulin in Type 1 Diabetic Patients. Effects on Glycemic Control and Counterregulation and Cognitive Performance During Hypoglycaemia

Trial Profile

Treatment With Liraglutide as add-on to Insulin in Type 1 Diabetic Patients. Effects on Glycemic Control and Counterregulation and Cognitive Performance During Hypoglycaemia

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Sep 2016

At a glance

  • Drugs Liraglutide (Primary) ; Insulin
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms T1DMLIRA
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Sep 2016 Results (n=20) analysing the effect of liraglutide on cerebral electrical activity and cognitive performance, presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes.
    • 20 Oct 2015 Primary endpoint has not been met. (Change from baseline in HbA1c (glycosylated haemoglobin)), as per an article published in the Diabetes Care
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top